Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice

Autor: Charles Timäus, Miriam Meiser, Borwin Bandelow, Kirsten R. Engel, Anne M. Paschke, Jens Wiltfang, Dirk Wedekind

Publikováno v: BMC Psychiatry
BMC psychiatry 19(1), 393 (2019). doi:10.1186/s12888-019-2377-z
BMC Psychiatry, Vol 19, Iss 1, Pp 1-11 (2019)

Background The purpose of this study was to assess the pharmacological treatment strategies of inpatients with borderline personality disorder between 2008 and 2012. Additionally, we compared pharmacotherapy during this period to a previous one (1996

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::42a78061701cce6443605f503fd97954
https://pubmed.ncbi.nlm.nih.gov/31830934

Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na+channel inactivation

Autor: Heinz Beck, Christian Wolff, Isabelle Niespodziany, Thoralf Opitz, Dominik Holtkamp

Publikováno v: Epilepsia 58(1), 27-41 (2016). doi:10.1111/epi.13602

SummaryObjective In human epilepsy, pharmacoresistance to antiepileptic drug therapy is a major problem affecting ~30% of patients with epilepsy. Many classical antiepileptic drugs target voltage-gated sodium channels, and their potent activity in in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909862928a88a443ac3d0e29ba66ba30
https://doi.org/10.1111/epi.13602

(Invited) HfO2-Based RRAM for Embedded Nonvolatile Memory: From Materials Science to Integrated 1T1R RRAM Arrays

Autor: Christian Wenger, Christian Walczyk, Bernd Tillack, Damian Walczyk, Malgorzata Sowinska, Gunter Schoof, Valery Stikanov, T. Bertaud, Sebastian Thiess, Dirk Wolansky, Thomas Schroeder

Publikováno v: ECS transactions 50, 21-26 (2012). doi:10.1149/05004.0021ecst

This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65a5cc8bde20144f848f8a7e4cdb324c
https://doi.org/10.1149/05004.0021ecst

Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug

Autor: Nuno Pires, Anna Doeser, Christina Schaub, Mischa Uebachs, Maria João Bonifácio, Gesa Dickhof, Margit Reitze, Patrício Soares-da-Silva, Heinz Beck

Publikováno v: Brain 138(2), 371-387 (2014). doi:10.1093/brain/awu339

In human epilepsy, pharmacoresistance to antiepileptic drug therapy is a major problem affecting a substantial fraction of patients. Many of the currently available antiepileptic drugs target voltage-gated sodium channels, leading to a rate-dependent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecee5a26358a25acd99af6659cdfe6a9
https://pubmed.ncbi.nlm.nih.gov/25627234

Neural ECM and epilepsy

Autor: Grzegorz M. Wilczynski, Elodie Chabrol, Katarzyna Łukasiuk, Naiara Vazquez, Elizabeth M. Powell, Matthew C. Walker, Asla Pitkänen, Xavier Ekolle Ndode-Ekane, Alexander Dityatev, Stefanie Dedeurwaerdere

Publikováno v: Amsterdam [u.a.] : Elsevier, Progress in Brain Research 214, 229-262 (2014). doi:10.1016/B978-0-444-63486-3.00011-6
Brain Extracellular Matrix in Health and Disease / Pitkänen, Asla ; : Elsevier, 2014, ; ISSN: 00796123 ; ISBN: 9780444634863 ; doi:10.1016/B978-0-444-63486-3.00011-6

Currently, there are about 20 antiepileptic drugs on market. Still, seizures in about 30% of patients with epilepsy are not adequately controlled, or the drugs cause quality-of-life-compromising adverse events. Importantly, there are no treatments to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030aab596b2a1032db806460fb3fcf58
https://pub.dzne.de/record/144612